Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by high-performance liquid chromatography with electrochemical detection

Therapeutic Drug Monitoring

Volumn 19, Issue 3, 1997, Pages 307-313

  Aravagiri, Manickam ^a,b   Ames, Donna ^a   Wirshing, William C ^a   Marder, Stephen R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Electrochemical detection; High performance liquid chromatography; Olanzapine; Plasma level monitoring; Plasma level dose relationship; Schizophrenic patients

Indexed keywords

LY 170222; NEUROLEPTIC AGENT; OLANZAPINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; ELECTROCHEMICAL ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; STANDARD;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; MIDDLE AGED; PIRENZEPINE;

EID: 0031437166     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199706000-00011     Document Type: Article

References (13)

1. Snyder SH. Dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976;133:197-202.
2. Seeman P. Therapeutic receptor-blocking concentrations of neuroleptics. International Clin Psychopharmacol 1995;10:Suppl 3.5-13.
3. 4. Neuropsychopharmacology 1992;7:261-84.
4. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3.
5. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989;99:S47-S53.
6. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacology 1995; 15:24S-29S.
7. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology 1996;124:188-96.
8. Gerlach J, Peacock, L. New antipsychotics: the present status. International Clin Psychopharmacology 1995;10:Suppl 3.39-48
9. Van Putten T, Marder SH, Wirshing WC, Aravagiri M, Chabret N. Neuroleptic plasma levels. Schizophr Bull 1991;17:197-216.
10. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-51.
11. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996;124:87-94.
12. Beasley Jr CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, Olanzapine HGAP Study Group. Olanzapine versus placebo: results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 1996;124:159-67.
13. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B 1995;668:85-90.